⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1992222 | 0.74 | — | — | |
| SCHEMBL9004978 | 0.74 | — | — | |
| SCHEMBL3189246 | 0.72 | — | — | |
| SCHEMBL544996 | 0.72 | — | — | |
| SCHEMBL15287122 | 0.72 | — | — | |
| SCHEMBL2333009 | 0.72 | — | — | |
| Hydrochloric Acid SCHEMBL11189447 | 0.70 | — | — | |
| SCHEMBL7131646 | 0.67 | PGR (0.34) | — | |
| SCHEMBL12763640 | 0.67 | — | — | |
| SCHEMBL12444700 | 0.67 | PTPN11 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102093334-B | Method for synthesizing condensed ring thiophene compounds | UNIV ZHENGZHOU | 2013-05-08 | — | — | CN | claimed |
| CN-102093334-A | Method for synthesizing condensed ring thiophene compounds | UNIV ZHENGZHOU | 2011-06-15 | — | — | CN | claimed |
| EP-3604326-B1 | PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND | FUJIFILM CORP (JP) | 2026-01-07 | — | — | EP | disclosed |
| EP-4608988-A1 | CLOSED-LOOP OPTIMIZATION OF GENERAL REACTION CONDITIONS FOR HETEROARYL SUZUKI-MIYAURA COUPLING | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250115569-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | LARIO THERAPEUTICS LTD (GB) | 2025-04-10 | — | — | US | disclosed |
| WO-2025076088-A1 | LACTAMS FOR USE AS SARM1 INHIBITORS | GENENTECH, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| US-12247004-B2 | 2-amino-N-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use | Oxford Drug Design Limited (GB) | 2025-03-11 | — | — | US | disclosed |
| CN-114846000-B | 2-Amino-N- (amino-oxo-aryl-lambda 6-sulfinyl) acetamide compounds and therapeutic uses thereof | 牛津药物设计有限公司 | 2025-01-03 | — | — | CN | disclosed |
| EP-4436955-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | Lario Therapeutics Limited (GB) | 2024-10-02 | — | — | EP | disclosed |
| US-20240245699-A1 | PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SERVIER LAB (FR) | 2024-07-25 | — | — | US | disclosed |
| CN-118317950-A | Sulfonamide compounds for the treatment of neurological disorders | 拉里奥治疗有限公司 | 2024-07-09 | — | — | CN | disclosed |
| US-5693646-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-02 | — | — | US | disclosed |
| US-5693647-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-02 | — | — | US | disclosed |
| US-5688808-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-11-18 | — | — | US | disclosed |
| US-5688810-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-11-18 | — | — | US | disclosed |
| EP-0800519-A1 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 1997-10-15 | — | — | EP | disclosed |
| EP-0800393-A1 | 4,4-(DISUBSTITUTED)CYCLOHEXAN-1-ONE MONOMERS AND RELATED COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-10-15 | — | — | EP | disclosed |
| WO-1996019995-A1 | 4,4-(DISUBSTITUTED)CYCLOHEXAN-1-ONE MONOMERS AND RELATED COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-07-04 | — | — | WO | disclosed |
| WO-1996019458-A2 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1996-06-27 | — | — | WO | disclosed |
| US-5446051-A | Nervous system disorder and brain disorder | ELI LILLY AND COMPANY (US) | 1995-08-29 | — | — | US | disclosed |